← FDA Drug Approvals (Drugs@FDA)
NALTREXONE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: TEVA PHARMS USA INC · Approved 2023-07-06
Drug application
- FDA Application #
ANDA213195- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- NALTREXONE
- Generic name
- Naltrexone
- Active ingredients
- NALTREXONE
- Dosage form
- FOR SUSPENSION, EXTENDED RELEASE
- Route
- INTRAMUSCULAR
- Marketing status
- Discontinued
- Sponsor
- TEVA PHARMS USA INC
- First approval
- 2023-07-06
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown